SkinBioTherapeutics (SBTX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 9.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 29.00
  • 52 Week Low: 7.25
  • Currency: UK Pounds
  • Shares Issued: 200.38m
  • Volume: 59,297
  • Market Cap: £18.54m
  • Beta: 0.01

SkinBioTherapeutics to begin human study this month

By Josh White

Date: Monday 03 Sep 2018

LONDON (ShareCast) - (Sharecast News) - Life science company SkinBioTherapeutics updated the market on its stability testing on Monday, reporting that the stability criteria required for its human study had been met.
The AIM-traded firm said it now expected to begin the study in September, as planned.

"Demonstrating the extended stability of the cream formulation was a key step to commencing the human study," said chief executive officer Dr Cath O'Neill.

"This remains on track to start this month."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

SBTX Market Data

Currency UK Pounds
Share Price 9.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 29.00
52 Week Low 7.25
Volume 59,297
Shares Issued 200.38m
Market Cap £18.54m
Beta 0.01

SBTX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
69.96% below the market average69.96% below the market average69.96% below the market average69.96% below the market average69.96% below the market average
84.31% below the sector average84.31% below the sector average84.31% below the sector average84.31% below the sector average84.31% below the sector average
Price Trend
80.88% below the market average80.88% below the market average80.88% below the market average80.88% below the market average80.88% below the market average
34.55% below the sector average34.55% below the sector average34.55% below the sector average34.55% below the sector average34.55% below the sector average
Income Not Available
Growth
18.27% above the market average18.27% above the market average18.27% above the market average18.27% above the market average18.27% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average

SBTX Dividends

No dividends found

Trades for 03-May-2024

Time Volume / Share Price
16:26 17,500 @ 9.02p
16:18 10,000 @ 9.02p
15:27 11,013 @ 9.00p
15:16 13,467 @ 9.00p
14:04 4,545 @ 9.02p

SBTX Key Personnel

CEO Stuart Ashman
CFO Manprit Singh Randhawa

Top of Page